The improvement in efficacy was associated with a significantly greater increase in tumor-specific CD8 T cells in the peripheral blood and organs of mice treated with neoadjuvant vs. adjuvant immunotherapy, suggesting a more robust immune response in the setting of an intact primary tumor. Here, CD8A is linked to neoplasm.